%0 Systematic Review
%T The effects of various therapies on vulvovaginal atrophy and quality of life in gynecological cancer patients: a systematic review.
%A Medeiros AG
%A Cintra MMM
%A Dos Reis MA
%A Rocha LP
%A do Carmo Neto JR
%A Machado JR
%J Arch Gynecol Obstet
%V 310
%N 2
%D 2024 Aug 19
%M 38898186
%F 2.493
%R 10.1007/s00404-024-07552-9
%X <B>OBJECTIVE: </B>Tumors affecting the female genital tract and their treatments have the potential to induce adverse modifications in vaginal health and impact personal aspects of patient's lives. Vulvovaginal atrophy is one of the morphological changes observed in individuals with a history of gynecological cancer, influenced both by the biological environment of tumors and the main therapeutic modalities employed. Therefore, the purpose of this study was to identify approaches to treat vulvovaginal atrophy while assessing the impact on the emotional and sexual health of women diagnosed with gynecological cancers.<BR><B>METHODS: </B>To achieve this goal, a systematic review was conducted following the methodological guidelines outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The databases used for literature research were PubMed and Web of Science.<BR><B>RESULTS: </B>Initially, 886 articles were obtained. After eliminating duplicates and applying inclusion/exclusion criteria, seven articles were selected for analysis. The period of highest publication activity spanned from 2017 to 2020, with the majority conducted in Italy. Five treatment modalities were identified and categorized as vaginal suppository, oral medication, surgical procedure, CO2 laser therapy, and vaginal dilator. Twenty-four outcomes related to vaginal health and 30 outcomes related to overall, sexual, and emotional quality of life were analyzed.<BR><B>CONCLUSIONS: </B>In general, all interventions demonstrated the ability to improve vaginal health or, at the very least, the sexual health of patients. Thus, despite limitations, all treatments have the potential to address vulvovaginal atrophy in patients with a history of gynecological cancer.